Your browser doesn't support javascript.
loading
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.
Boguszewski, Margaret C S; Boguszewski, Cesar L; Chemaitilly, Wassim; Cohen, Laurie E; Gebauer, Judith; Higham, Claire; Hoffman, Andrew R; Polak, Michel; Yuen, Kevin C J; Alos, Nathalie; Antal, Zoltan; Bidlingmaier, Martin; Biller, Beverley M K; Brabant, George; Choong, Catherine S Y; Cianfarani, Stefano; Clayton, Peter E; Coutant, Regis; Cardoso-Demartini, Adriane A; Fernandez, Alberto; Grimberg, Adda; Guðmundsson, Kolbeinn; Guevara-Aguirre, Jaime; Ho, Ken K Y; Horikawa, Reiko; Isidori, Andrea M; Jørgensen, Jens Otto Lunde; Kamenicky, Peter; Karavitaki, Niki; Kopchick, John J; Lodish, Maya; Luo, Xiaoping; McCormack, Ann I; Meacham, Lillian; Melmed, Shlomo; Mostoufi Moab, Sogol; Müller, Hermann L; Neggers, Sebastian J C M M; Aguiar Oliveira, Manoel H; Ozono, Keiichi; Pennisi, Patricia A; Popovic, Vera; Radovick, Sally; Savendahl, Lars; Touraine, Philippe; van Santen, Hanneke M; Johannsson, Gudmundur.
Afiliación
  • Boguszewski MCS; Department of Pediatrics, Federal University of Paraná, Curitiba, Brazil.
  • Boguszewski CL; SEMPR (Endocrine Division), Department of Internal Medicine, Federal University of Parana, Curitiba, Brazil.
  • Chemaitilly W; Division of Endocrinology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Cohen LE; Division of Endocrinology and Diabetes, Department of Pediatrics, The Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, New York, USA.
  • Gebauer J; Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Luebeck, Germany.
  • Higham C; Department of Endocrinology, Christie Hospital NHS Foundation Trust, University of Manchester, and Manchester Academic Health Science Centre, Manchester, UK.
  • Hoffman AR; Stanford University School of Medicine, Stanford, California, USA.
  • Polak M; Department of Pediatric Endocrinology, Gynecology and Diabetology, Hôpital Universitaire Necker Enfants Malades, AP-HP, Université de Paris, Paris, France.
  • Yuen KCJ; Barrow Pituitary Center, Barrow Neurological Institute, Phoenix, Arizona, USA.
  • Alos N; Department of Neuroendocrinology, St. Joseph's Hospital and Medical Center, University of Arizona College of Medicine and Creighton School of Medicine, Phoenix, Arizona, USA.
  • Antal Z; Division of Endocrinology, Sainte-Justine University Hospital Centre, University of Montreal, Montreal, Quebec, Canada.
  • Bidlingmaier M; Memorial Sloan-Kettering Cancer Center and Weill Cornel Medicine New York Presbyterian Hospital, New York, New York, USA.
  • Biller BMK; Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich, Germany.
  • Brabant G; Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Choong CSY; Department of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, University of Manchester, Manchester, UK.
  • Cianfarani S; Department of Endocrinology and Diabetes, Perth Children's Hospital, Child & Adolescent Health Service, Perth, Australia.
  • Clayton PE; Division of Paediatrics, Faculty of Health & Medical Sciences, University of Western Australia, Perth, Australia.
  • Coutant R; Department of Systems Medicine, University of Rome Tor Vergata, Rome Italy.
  • Cardoso-Demartini AA; Dipartimento Pediatrico Universitario Ospedaliero, IRCCS 'Bambino Gesu' Children's Hospital, Rome Italy.
  • Fernandez A; Department of Women's and Children's Health, Karolinska Institute and University Hospital, Stockholm, Sweden.
  • Grimberg A; Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK.
  • Guðmundsson K; Department of Pediatric Endocrinology, University Hospital, Angers, France.
  • Guevara-Aguirre J; Pediatric Endocrinology Unit, Department of Pediatrics, Hospital de Clínicas, Federal University of Parana, Curitiba, Brazil.
  • Ho KKY; Endocrinology Department, Hospital Universitario de Mostoles, Mostoles, Spain.
  • Horikawa R; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Isidori AM; Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Jørgensen JOL; Children's Medical Center, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland.
  • Kamenicky P; Department of Diabetes and Endocrinology, College of Medicine, Universidad San Francisco de Quito at Quito, Quito, Ecuador.
  • Karavitaki N; The Garvan Institute of Medical Research and St. Vincent Hospital, Sydney, Australia.
  • Kopchick JJ; Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan.
  • Lodish M; Department of Experimental Medicine, Sapienza University of Rome, Roma, Italy.
  • Luo X; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • McCormack AI; Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Le Kremlin-Bicêtre, France.
  • Meacham L; Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Melmed S; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK.
  • Mostoufi Moab S; Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Müller HL; Edison Biotechnology Institute and Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.
  • Neggers SJCMM; Division of Pediatric Endocrinology and Diabetes, University of California, San Francisco, California, USA.
  • Aguiar Oliveira MH; Department of Pediatrics, Tongji Hospital, Tonji Medical College, Hu, China.
  • Ozono K; Department of Endocrinology, St Vincent's Hospital, Sydney, Australia.
  • Pennisi PA; Hormones and Cancer Group, Garvan Institute of Medical Research, Sydney, Australia.
  • Popovic V; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia.
  • Radovick S; Children's Healthcare of Atlanta Aflac Cancer and Blood Disorders Service, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
  • Savendahl L; Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Touraine P; Divisions of Oncology and Endocrinology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • van Santen HM; Department of Pediatrics and Pediatric Hematology/Oncology, University Children's Hospital, Klinikum Oldenburg AöR, Carl von Ossietzki University Oldenburg, Oldenburg, Germany.
  • Johannsson G; Department of Medicine, Erasmus University Medical Centre, Rotterdam, the Netherlands.
Eur J Endocrinol ; 186(6): P35-P52, 2022 04 21.
Article en En | MEDLINE | ID: mdl-35319491
ABSTRACT
Growth hormone (GH) has been used for over 35 years, and its safety and efficacy has been studied extensively. Experimental studies showing the permissive role of GH/insulin-like growth factor 1 (IGF-I) in carcinogenesis have raised concerns regarding the safety of GH replacement in children and adults who have received treatment for cancer and those with intracranial and pituitary tumours. A consensus statement was produced to guide decision-making on GH replacement in children and adult survivors of cancer, in those treated for intracranial and pituitary tumours and in patients with increased cancer risk. With the support of the European Society of Endocrinology, the Growth Hormone Research Society convened a Workshop, where 55 international key opinion leaders representing 10 professional societies were invited to participate. This consensus statement utilized (1) a critical review paper produced before the Workshop, (2) five plenary talks, (3) evidence-based comments from four breakout groups, and (4) discussions during report-back sessions. Current evidence reviewed from the proceedings from the Workshop does not support an association between GH replacement and primary tumour or cancer recurrence. The effect of GH replacement on secondary neoplasia risk is minor compared to host- and tumour treatment-related factors. There is no evidence for an association between GH replacement and increased mortality from cancer amongst GH-deficient childhood cancer survivors. Patients with pituitary tumour or craniopharyngioma remnants receiving GH replacement do not need to be treated or monitored differently than those not receiving GH. GH replacement might be considered in GH-deficient adult cancer survivors in remission after careful individual risk/benefit analysis. In children with cancer predisposition syndromes, GH treatment is generally contraindicated but may be considered cautiously in select patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Hipofisarias / Hormona de Crecimiento Humana Tipo de estudio: Prognostic_studies / Qualitative_research Límite: Adult / Child / Humans Idioma: En Revista: Eur J Endocrinol Asunto de la revista: ENDOCRINOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Brasil
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Hipofisarias / Hormona de Crecimiento Humana Tipo de estudio: Prognostic_studies / Qualitative_research Límite: Adult / Child / Humans Idioma: En Revista: Eur J Endocrinol Asunto de la revista: ENDOCRINOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Brasil